References
- Ashokkumar P, Sudhandiran G. 2008. Protective role of luteolin on the status of lipid peroxidation and antioxidant defense against azoxymethane-induced experimental colon carcinogenesis. Biomedicine and Pharmacotherapy. 62: 590–597.
- Bates DO, Hillman NJ, Williams B, Neal CR, Pocock TM. 2002. Regulation of Microvascular Permeability by Vascular Endothelial Growth Factors. Journal of Anatomy. 200: 581–597.
- Byun S, Lee KW, Jung SK, Lee EJ, Hwang MK, Lim SH, Bode AM, Lee HJ, Dong Z. 2010. Luteolin inhibits protein kinase C(epsilon) and c-Src activities and UVB-induced skin cancer. Cancer Research. 70(6):2415–2423.
- Chen LL, Deng H, Cui H, Fang J, Zuo Z, Deng JL, Li Y, Wang X, Zhao L. 2018. Inflammatory responses and inflammation-associated diseases in organs. Oncotarget. 23; 9(6): 7204–7218.
- Chen CY, Peng WH, Tsai KD, Hsu SL. 2007. Luteolin suppresses inflammation-associated gene expression by blocking NF-κB and AP-1 activation pathway in mouse alveolar macrophages. Life Sciences. 81:1602–1614.
- Crul T, Maléth J. 2021. Endoplasmic Reticulum-Plasma Membrane Contact Sites as an Organizing Principle for Compartmentalized Calcium and cAMP Signaling. Int. J. Mol. Sci. 22(9), 4703;
- Dempsey EC, Newton AC, Mochly-Rosen D, Fields AP, Reyland ME, Insel PA, Messing RO. 2000. Protein kinase C isozymes and the regulation of diverse cell responses. America Journal of Physiology. Lung Cell and Molecular Physiology. 279: L429–L438.
- Gerald K. 2005. Cell and Molecular Biology. In cell signaling and signal transduction, ed Patrick Fitzgerald and Geraldine Osnato, pp 635–636. United States of America: John Wiley and Sons, Inc.
- Gifford SM, Grummer MA, Pierre SA, Austin JL, Zheng J, Bird IM. 2004. Functional characterization of HUVEC-CS: Ca 2+ signaling, ERK 1/2 activation, mitogenesis and vasodilator production. Journal of Endocrinology. 182, 485–499
- Glass CA, Bates DO. 2003. Role of endothelial Ca2+ stores in the regulation of hydraulic conductivity of Rana microvessels in vivo. American Journal of Physiology. Heart Circulation Physiology 284: H1468–1478.
- Grynkiewicz G, Poenie M, Tsien RY. 1985 A new generation of Ca2+ indicators with greatly improved fluorescence properties. Journal of Biology and Chemistry. 260: 3440–3450.
- Gutterman DD. 2002. Vascular dysfunction in hyperglycemia: is protein kinase C the culprit? Circulation Research. 90: 5–7.
- Hu G, Aaron T, Richard P, Minshall D. 2007. Caveolin regulation of endothelial function. Chemico-Biological Interactions. 7:35–43
- Jia Z, Nallasamy P, Liu D, Shah H, Li JZ, Chitrakar R, Si H, McCormick J, Zhu H, Zhen W, Li Y. 2015. Luteolin protects against vascular inflammation in mice and TNF-alpha-induced monocyte adhesion to endothelial cells via suppressing IKBα/NF-κB signaling pathway. Journal of Nutritional Biochemistry. 26(3), 293–302.
- Johnson A, Hocking DC, Ferro TJ. 1990. Mechanism of pulmonary edema induced by a diacylglycerol second messenger. America Journal of Physiology. 258: H85–H91.
- Kimata M, Shichijo M, Miura T, Serizawa I, Inagaki N, Nagai H. 2000. Effects of luteolin, quercetin and baicalein on immunoglobulin E-mediated mediator release from human cultured mast cells. Clin Exp Allergy. 30(4):501–508.
- Li RL, Wang LY, Duan HX, Qian D, Zhang Q, He LS, Li XP. 2023. Natural flavonoids derived from herbal medicines are potential anti-atherogenic agents by inhibiting oxidative stress in endothelial cells. Front Pharmacol. 14: 1141180.
- Li H, Zhang Q. 2023. Research Progress of Flavonoids Regulating Endothelial Function Pharmaceuticals, 16(9), 1201.
- Lin Y, Shi R, Wang X, Shen HM. 2008. Current Cancer Drug Targets. In Luteolin, a flavonoid with potential for cancer prevention and therapy, pp 634–646(13). Bentham Science Publishers.
- Luo JL, Maeda S, Hsu LC, Yagita H, Karin M. 2004. Inhibition of NF-kappa B in cancer cells converts inflammation-induced tumor growth mediated by TNF alpha to TRAIL-mediated tumor regression. Cancer Cell. 6:297–305.
- Maravall M, Mainen ZF, Sabatini BL, Svoboda K. 2000. Estimating Intracellular Calcium Concentrations and Buffering without Wavelength Ratioing. Biophysic Journal. 78, 5, 2655–2667
- Mehta D, Malik AB. 2006. Signaling mechanisms regulating endothelial permeability, Physiology. Review. 86: 279–367.
- Mehta D, Rahman A, Malik AB. 2001. Protein kinase C-alpha signals rho-guanine nucleotide dissociation inhibitor phosphorylation and rho activation and regulates the endothelial cell barrier function. Journal of Biology and Chemistry. 276: 22614–22620.
- Pan D, Xu L, Xu L, Guo M, Guo M. 2022. The role of protein kinase C in diabetic microvascular complications. Frontiers Endocrinology. 13: 973058.
- Qin X, Qin H, Li Z, Xue S, Huang B, Liu X, Wang D. 2022. Luteolin alleviates ischemia/reperfusion injury-induced no-reflow by regulating Wnt/β-catenin signaling in rats. Microvascular Research. 139: 104266.
- Sandoval R, Malik AB, Minshall RD, Kouklis P, Ellis CA, Tiruppathi C. 2001. Ca2+ signalling and PKCalpha activate increased endothelial permeability by disassembly of VE-cadherin junctions. Journal of Physiology. 533: 433–445.
- Serhan CN, Savill J. 2005. Resolution of inflammation: the beginning programs the end. Natural Immunology. 6 (12): 1191–7.
- Tawornchat P, Pattarakankul T, Palaga T, Intasanta V, Wanichwecharungruang S. 2021. Polymerized Luteolin Nanoparticles: Synthesis, Structure Elucidation, and Anti-Inflammatory Activity. ACS Omega. 2; 6(4): 2846–2855.
- Terzuoli E, Corti F, Nannelli G, Giachetti A, Donnini S, Ziche M. 2018. Bradykinin B2 Receptor Contributes to Inflammatory Responses in Human Endothelial Cells by the Transactivation of the Fibroblast Growth Factor Receptor FGFR-1. Int J Mol Sci. 19(9): 2638.
- Wolf BA, Easom RA, McDaniel ML, Turk J. 1990. Diacylglycerol synthesis de novo from glucose by pancreatic islets isolated from rats and humans. Journal of Clinical Investigation. 85: 482–490.
- Wu HM, Yuan HY, Zawieja DC, Tinsley J, Granger HJ. 1999. Role of phospholipase C, protein kinase C, and calcium in VEGF-induced venular hyperpermeability. America Journal of Physiology. 276: H535–542.